MMB is a biopharmaceutical contract manufacturing organization with a core expertise in the development and clinical manufacturing of viral products for pharmaceutical companies to test treatments and vaccines.

According to Sigma-Aldrich president Frank Wicks, the company acquired MMB to continue their "push into niche biologics, giving us the critical capability to manufacture virus."